ArticleAsian Pacific journal of cancer prevention : APJCP2025
Investigation Role of Toll-like Receptor-9 Gene and miR-155 Expression Levels in Acute Myeloid Leukemia via Quantitative Real-Time PCR.
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Non-Coding Code: Silent Regulators of MEG3 and Let-7i-3p/5p in the Progression of Acute Lymphoblastic Leukemia.Asian Pacific journal of cancer prevention : APJCP · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to investigate the mRNA expression levels of Toll-like receptor 9 and microRNA-155 in Iraqi patients diagnosed with acute myeloid leukemia (AML) within a case-control study framework. Additionally, the study will assess relevant hematological parameters.
methodsThis study enrolled 40 Iraqi patients diagnosed with AML who were undergoing chemotherapy and experiencing relapse, and 40 healthy individuals as a control group. Hematological parameters were measured using a complete blood count (CBC) device. RNA was extracted from samples, quantified, and assessed for purity. Subsequently, RNA was reverse-transcribed into complementary DNA (cDNA). The relative expression levels of TLR-9 and miR-155 genes were quantified using quantitative real-time polymerase chain reaction (qRT-PCR).
resultHemoglobin, erythrocyte, hematocrit, and platelet levels exhibited significant differences between AML patients and healthy controls. In contrast, white blood cell and lymphocyte counts were not significantly different between the two groups. TLR-9 gene expression was comparable between healthy controls and AML patients, with fold change values of 1.000 and 1.49, respectively. However, miR-155 expression was significantly lower in AML patients compared to healthy controls, with fold change values of 0.608 and 1.000, respectively.
conclusionTo evade host immune surveillance, cancer cells may downregulate the expression of TLR-9 and miR-155. This dysregulation may contribute to the progression and development of AML. Furthermore, the downregulation of miR-155 and dysregulation of TLR-9 during oncogenesis may serve as potential prognostic markers for AML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.